ALL-220 Azacitidine in Combination With Venetoclax Maintenance Post Allogeneic Hematopoietic Cell Transplantation in T-Cell Acute Lymphoblastic Leukemia

The landscape of alterations affecting epigenetic regulators in T‐cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities

“…125 In a separate study of relapsed/ refractory T-ALL, five adult patients were salvaged when treated with a combination of venetoclax (BCL2 inhibitor) and decitabine. 126,127 For clinical cases that underwent allogenic hematopoietic stem cell transplantation (allo-HSCT), one study showed that low dose decitabine after allo-HSCT prevented relapse in 7/7 T-ALL patients (including one ETP-ALL case) 128 and another study showed that combining decitabine with venetoclax prevented relapse in 4/4 T-ALL patients up to 15 months after transplant. 126,127 Taken together, these studies all provide strong support for the use of decitabine as a maintenance therapy in T-ALL.…”

“…126,127 For clinical cases that underwent allogenic hematopoietic stem cell transplantation (allo-HSCT), one study showed that low dose decitabine after allo-HSCT prevented relapse in 7/7 T-ALL patients (including one ETP-ALL case) 128 and another study showed that combining decitabine with venetoclax prevented relapse in 4/4 T-ALL patients up to 15 months after transplant. 126,127 Taken together, these studies all provide strong support for the use of decitabine as a maintenance therapy in T-ALL. [129][130][131] The HDACi Givinostat exerted robust cytotoxic effect and induction of DNA damage (increased phospho-H2AX levels) in vivo for the treatment of T-ALL pediatric PDXs (n = 9).…”

“…ChiCTR1800014888 [125][126][127][128] Using mouse xenografts, it was identified that 5-azacytidine treated hypermethylated T-ALL samples showed delayed tumor progression.…”

“…Of these six patients, three cases had no response, one had complete response with incomplete recovery of platelets, one case with complete response in the marrow after decitabine single agent treatment, and one case having a complete response in the marrow with decitabine and Hyper‐CVAD treatment 125 . In a separate study of relapsed/refractory T‐ALL, five adult patients were salvaged when treated with a combination of venetoclax (BCL2 inhibitor) and decitabine 126,127 . For clinical cases that underwent allogenic hematopoietic stem cell transplantation (allo‐HSCT), one study showed that low dose decitabine after allo‐HSCT prevented relapse in 7/7 T‐ALL patients (including one ETP‐ALL case) 128 and another study showed that combining decitabine with venetoclax prevented relapse in 4/4 T‐ALL patients up to 15 months after transplant 126,127 .…”